To investigate the role of MED12 in prostate cancer, we analyzed aberrations in the MED12 gene copy number status in 2 publicly available datasets: treatment-naïve (TCGA-PRAD, primary prostate cancer) and CRPC (SU2C-PRAD, predominantly metastatic prostate cancer) tissues. This evidence concerns the gene MED12 and Familial prostate cancer.